SCHEMBL29871985

SCHEMBL29871985

CC(C)(O)c1ccc2c(c1)C(=O)NC2c1ccc(C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.39
KDM1A O60341 2/20 0.38
PARP1 P09874 2/20 0.38
PARP2 Q9UGN5 1/20 0.38
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
PARP10 Q53GL7 1/20 0.36
TNKS O95271 1/20 0.35
TNKS2 Q9H2K2 1/20 0.35
PARP3 Q9Y6F1 1/20 0.35
TSHR P16473 1/20 0.35
CNR1 P21554 1/20 0.35
KCNH2 Q12809 1/20 0.35
HTR2C P28335 1/20 0.34
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22769969 0.77 PARP1 (0.51) ESR1PARP1PARP2KMT2ATNKS
SCHEMBL29872089 0.77 PARP1 (0.51) ESR1PARP1PARP2KMT2ATNKS
SCHEMBL31739118 0.71 PARP1 (0.43) PARP1CHRNB2CHRNA4PARP10HTR2C
SCHEMBL30079832 0.69 TP53 (0.40)
SCHEMBL30079622 0.66 TP53 (0.38) CHRNB2CHRNA4
SCHEMBL1536352 0.65 KIF11 (0.48) MEN1KMT2ATSHRALDH1A1
SCHEMBL31599422 0.65 PARP1 (0.38) PARP1CHRNB2CHRNA4PARP10PIM1
SCHEMBL11195319 0.65 HSD17B10 (0.43) PARP1MEN1KMT2APARP10
SCHEMBL21250244 0.64 HTR7 (0.45) PARP1MEN1KMT2ATSHRALDH1A1
SCHEMBL31472221 0.64 MDM2 (0.34) ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108473464-B Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity 阿斯泰克斯治疗有限公司 2022-08-23 CN claimed
CN-108473464-B Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity 阿斯泰克斯治疗有限公司 2022-08-23 CN disclosed